NANOBIOTIX Provides First Quarter 2023 Operational and Financial Update
Reported €30.2 million in cash and cash equivalents as of March 31, 2023PARIS and CAMBRIDGE, Mass., May 17, 2023 -- NANOBIOTIX , a late-clinical stage biotechnology company pioneering... | May 17, 2023
Source: marketscreener.com